Refer a Patient

Have a Patient with Schizophrenia Who May Be Interested in the Journey Studies?

The Journey Studies are evaluating the efficacy, safety, and tolerability of the investigational study drug valbenazine, compared to placebo, as adjunctive treatment in patients with schizophrenia who have had an inadequate response to antipsychotic treatment.

Study Design

These are double-blinded studies in which approximately 400 participants will be randomized to receive either valbenazine or placebo, both taken as oral capsules once a day.

Qualifying Criteria

Key Inclusion Criteria

  • Male or female patients aged ≥ 18 years of age.
  • Medically confirmed diagnosis of schizophrenia ≥ 1 year prior to the screening visit.
  • Patient is receiving background antipsychotic therapy (other than clozapine) at a total daily dose as confirmed by pharmacy records or, if available, additional records/documentation.
  • The patient must have an adult informant (e.g., family member, social worker, caseworker, residential facility staff, or nurse) who meets the following requirements:
    • Spends ≥ 2 hours/week with the patient.
    • Is able to provide input for the clinicians completing study rating scales.
    • Is able and willing to provide written informant consent. Informant consent is separate from the subject’s written informed consent and must be signed before the patient will be considered eligible for the studies.
    • Is able to participate in at least 1 in-person or remote interview at the study site during the screening period (between the screening visit and Day 1) and able to provide continuing input by attending corresponding on-site visits or participating in telephone interviews.

Other inclusion and exclusion criteria apply.

Key Exclusion Criteria

  • Pregnant, or breastfeeding, or plans to become pregnant during the studies.
  • Patient has comorbid Parkinsonism.
  • Have a Barnes Akathisia Rating Scale (BARS) global clinical assessment score ≥ 2 at the screening visit (Visit 1).
  • Patient has a history of treatment-resistant schizophrenia as defined by any of the following:
    • History of clozapine treatment for treatment-resistant psychosis; or
    • History of multiple adequate and failed antipsychotic medication trials where subject demonstrated minimal or no improvement (failure to tolerate a medication does not constitute failure to respond).
  • Has any of the following:
    • A diagnosis of schizoaffective disorder.
    • A diagnosis of bipolar disorder.
    • A lifetime diagnosis of obsessive-compulsive disorder.
    • A diagnosis of moderate or severe substance use disorder.
  • A recent (within the last 6 months before the screening visit) occurrence of panic disorder, depressive episode, or other comorbid psychiatric conditions currently requiring clinical attention.
  • Is at imminent risk of suicide or injury to self, others, or property, or the subject has attempted suicide within 1 year prior to the screening visit.
  • Positive alcohol test or urine drug screen for disallowed substances, including amphetamines, barbiturates, cocaine, marijuana, methadone, methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA), phencyclidine, or nonprescribed benzodiazepines or opiates.

Other inclusion and exclusion criteria apply.

Journey Studies Research Sites

If you have a patient who may be interested in participating, and you think may qualify, refer your patient to this study website to take the prescreening questionnaire to determine eligibility, or fill out a contact request form if you would like to request contact directly from an active research site.

Find the Site Nearest You

Enter your zip code below or click on the map to find the participating research site(s) nearest you.

View full list of locations.

Active site locations

Future site locations